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Abstract: Glioblastoma (GBM) is a fast-growing type of malignant primary brain tumor. To explore the
mechanisms in GBM, complex biological networks are used to reveal crucial changes among different
biological states, which reflect on the development of living organisms. It is critical to discover the
kernel differential subgraph (KDS) that leads to drastic changes. However, identifying the KDS is
similar to the Steiner Tree problem that is an NP-hard problem. In this paper, we developed a criterion
to explore the KDS (CKDS), which considered the connectivity and scale of KDS, the topological
difference of nodes and function relevance between genes in the KDS. The CKDS algorithm was
applied to simulated datasets and three single-cell RNA sequencing (scRNA-seq) datasets including
GBM, fetal human cortical neurons (FHCN) and neural differentiation. Then we performed the
network topology and functional enrichment analyses on the extracted KDSs. Compared with the
state-of-art methods, the CKDS algorithm outperformed on simulated datasets to discover the KDSs.
In the GBM and FHCN, seventeen genes (one biomarker, nine regulatory genes, one driver genes,
six therapeutic targets) and KEGG pathways in KDSs were strongly supported by literature mining
that they were highly interrelated with GBM. Moreover, focused on GBM, there were fifteen genes
(including ten regulatory genes, three driver genes, one biomarkers, one therapeutic target) and
KEGG pathways found in the KDS of neural differentiation process from activated neural stem cells
(aNSC) to neural progenitor cells (NPC), while few genes and no pathway were found in the period
from NPC to astrocytes (Ast). These experiments indicated that the process from aNSC to NPC
is a key differentiation period affecting the development of GBM. Therefore, the CKDS algorithm
provides a unique perspective in identifying cell-type-specific genes and KDSs.
Keywords: glioblastoma; kernel differential subgraph; complex networks; single-cell; scRNA-seq
1. Introduction
Glioblastoma (GBM) is one of the most common and lethal primary tumors, which has a poor
prognosis and patients usually survive less than 15 months following diagnosis [1,2]. It is notoriously
difficult to treat due to its diffuse nature and our limited knowledge of its molecular pathogenesis [3].
The important steps for determining the optimal therapeutic strategies are understanding the
mechanisms of the dynamic processes and identification of new potential biological modules.
Compared with the bulk RNA sequencing, single-cell RNA sequencing (scRNA-seq) can provides
important information for inter-cellular transcriptomic heterogeneity and dissecting the interplay
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between the cancer cells and the associated microenvironment. scRNA-seq is increasingly used to
study gene expression at the level of individual cells and graduated processes such as development and
differentiation, adding another dimension to understand gene expression regulation and dynamics [4].
Occurrence and development of cancers are governed by complex networks of interacting intercellular
and intracellular signals [5,6].
Complex biological networks are able to reveal biological mechanisms [7]. Moreover, differential
network is often used to identify the kernel modules causing diversity by integrating dynamic gene
expression changes. Bai Zhang proposed the differential dependency network (DNN) method [8],
which is based on local dependency, to detect topological changes across different biological conditions.
A differential network-based methodology [9] can identify candidate target genes and chemical
compounds for reverting disease phenotypes. BioNetStat is a tool for biological networks differential
analysis by the methods grounded on network theory [10]. Furthermore, crucial changes among
networks of different states are capable of reflecting on the development of living organisms [11].
Therefore, it is critical to discover the kernel differential subgraph (KDS) which leads to drastic
changes. Discovering the KDS is similar to the Steiner Tree problem which is a NP-hard problem [12].
Topology-based KDS (TKDS) [13] is a method to discover the KDS from gene regulatory networks of
omics datasets. SMT-Neurophysiology [12] is a tool in the form of an approximation to the Steiner
Minimal Tree (SMT) algorithm, which is to find biomedically-meaningful KDS in neurophysiology.
These methods could discover the KDS in different states. However, the accuracy of these methods
was not high enough. And moreover, these methods did not fully consider the changes of topology.
The kernel differential subgraph (KDS) is a small-scale connected network with the differential
nodes and edges. Considering the multiple factors affecting the subgraph, we developed a criterion to
discover the kernel differential subgraph (CKDS). Specially, the criterion considers the connectivity
and scale of KDS, the topological difference of nodes and function relevance between genes in the KDS.
To demonstrate the effectiveness of our method, we applied CKDS to simulated datasets and three
scRNA-seq datasets including GBM, fetal human cortical neurons (FHCN) and neural differentiation.
Additional network topology and functional enrichment analyses were performed on the extracted
KDSs influencing GBM closely.
2. Materials and Methods
2.1. A Framework of a Criterion to Discover the Kernel Differential Subgraph (CKDS)
2.1.1. Raw Data Pre-Treatment and Differential Expressed Genes Identification
Raw scRNA-seq counts data is usually downloaded from the Gene Expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/geo/). The raw counts data is converted to read-counts-per-million (CPM)
gene expression matrix using the ‘cpm’ function by R package ‘edgeR’ [14]. The processed matrix is
divided into cancer and normal gene expression matrix shown in Figure 1.
Differential expressed genes (DEGs) are detected from the processed scRNA-seq data by R package
‘edgeR’. Similar to the analysis of differential gene expression, we use ‘p-value, p.adjust and log2FC’ to
obtain the DEGs by the gene expression. The R function ‘p.adjust’ is to adjust the p-values by ‘false
discovery rate (fdr)’ method [15]. Fold change (FC) [16] is calculated simply as the ratio of the difference
between final value and the initial value over the original value. In the field of bioinformatics, we
commonly use log2 for expressing the FC (log2FC). The genes with the p-value < 0.01, p.adjust < 0.05
and
∣∣∣log2FC∣∣∣ > 2 are considered as DEGs.
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Figure 1. The overall framework for criterion to explore the kernel differential subgraph (CKDS). KDS:
kernel differential subgraph.
2.1.2. Single-Cell Transcriptome Network Construction by Differential Expressed Genes
Single-cell transcriptome data may lead to high false positives [17]. Therefore, integrated
multi-omics data analysis has become a trend to solve it in biological network analysis [18]. Proteomics
and transcriptomics data are integrated to construct a network [19], in which protein–protein networks
(PPN) are used as a backbone network, and Pearson correlation coefficient (PCC) between expression
of each pair of genes is used as the weight of edge. In this work, DEGs are connected with known
protein–protein interactions (PPIs) documented in STRING database (v10.5, https://string-db.org/cgi/
input.pl). Previous research has shown that when applied to real data, only edges with top 10% PCC
were reserved [20]. In the generated STRING network, compared with the original one, over 90%
edges disappear, d due to the generic property th t the ne work structu would remain stable
during the stable biological stage. At the same time, in rder to ensure the effectiveness of PCC, we set
|PCC| ≥ 0.6 [21]. Thus, the association of two differential genes is defined as the weight of the edge,
and only gen s with the value of top 10% PCC and |PCC| ≥ 0.6 are reserved.
2.1.3. Calculating Differential Value of Genes by Graphlet Vector
Graphlets are small c nnected non-isomorphic induced subgraphs containing 2, 3, 4, or more
n des [22–24]. Th graphlets of 2–4 nodes are shown in Figure 2. For 2, 3, n 4-node graphlets, th
nodes in same color mean the no es with the same topological structur (degree). There are 15 different
kinds of nodes labelled orbits0-orbits14. Eac node in th network obtains specific graphlet vector by
calculating the frequency in 15 dimensions.
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For the node u ∈ V,u′ ∈ V′, ui denotes the ith coordinate of its signature vector, i.e. ui is the
number of times node u is touched by an orbit i in V. The distance Di(u,u′) between the ith orbits of
nodes u and u′ is defined as [25]:
Di(u,u′) = wi ×
∣∣∣log(ui + 1) − log(u′i + 1)∣∣∣
log(max{ui,u′i}+ 2) (1)
where wi is the weight of orbit i that accounts for dependencies between orbits [25].
As shown in Equation (2), the d-value between nodes u and u′ means the total distance.
d− value(u,u′) =
∑14
i=0 Di(u,u
′)∑14
i=0 wi
(2)
The distance d− value(u,u′) is in (0, 1), where distance 0 means that signatures of nodes u and
u′ are identical [25]. The more topological structure varies, the larger d-value is. Nodes with d-value
larger than 0.4 [23] are selected into the differential nodes set D for the further analysis.
2.1.4. The Criterion to Extract Kernel Differential Subgraph
Kernel differential subgraph extraction is similar to Steiner Tree problem, which is an NP-hard
problem. In this work, the criterion to extract KDS is present by four principles. Firstly, the subgraph
should be connected. A connected subgraph can discover the dense relationship between molecules.
Secondly, the scale of subgraph should be as small as possible. A KDS is the most core subgraph
with small scale of the entire network. Thirdly, the d-value of nodes with large topological difference
calculated by graphlet should be as large as possible. Nodes with large differences in topology are often
key nodes in the network. These nodes will be selected to extract the KDS. Fourthly, the functional
relevance between genes should be as strong as possible. It means the higher weight of edges will be
chosen to extract the KDS.
There is a cancer networkG(V,E) and a normal networkG′(V,E′) representing two different states.
V represents the set of v common nodes; E and E′ represent the set of edges respectively. Algorithm 1
describes the criterion to discover the KDS (CKDS), where We represents the weight set of edges. The set
D = {D1,D2, . . . ,Dv} represents the set of differential nodes with d-value d = {d1, d2, . . . , dv}. According
to the sorted d-value d in descending order, we selected the differential nodes Dv (dv ≥ 0.4) [23] to
add in KDS. When considering a new path added to KDS,
∑
dv and
∑
We mean the sum of d-value
of all nodes and weight of all edges on the path. The parameter a and b were coefficient designed to
measure the importance of
∑
Dv and
∑
We. The estimation of the vector (a, b) is discussed in Section 3.
KDSx (KDS1 and KDS2) indicates the KDS of different state. The pseudo code of this algorithm is
shown below.
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Algorithm 1: the criterion to discover the KDS (CKDS)
Input: network G, network G′, common differential node set D = {D1,D2, . . . ,Dv}with their d-value
d = {d1, d2, . . . , dv}.
Output: KDS of G and G′.
Sort D by their d-value d in descending order
For x from 1 to 2
Add D1 to KDSx
For Dv(v ≥ 2 and dv ≥ 0.4) in sorted D do
if Dv is existed in KDSx
continue
else if
if Dv directly connect with any node existed in KDSx
add Dv and its edge to KDSx
else if
calculate the score of the shortest paths from Dv to each node in KDSx by
Equation (3),
Scorepath = a ∗
∑
dv + b ∗
∑
We (3)
Add the path that has the highest Scorepath to KDSx
End
Return KDSx
End
Intersect KDS1 and KDS2 to get KDS of G and G′
After getting the KDS of G and G′, the KDS was constructed by Cytoscape (http://www.cytoscape.
org/) [26].
2.2. Topological Analyses on Kernel Differential Subgraph
The centrality indexes including degree centrality (DC) [27], betweenness centrality (BC) [28],
closeness centrality (CC) [29], and eigenvector centrality (EC) [30] were used to analyze the KDS. For a
KDS G = (V,E), V and E represent the set of nodes and edges respectively. Four centrality indexes are
defined as follows,
DC: DC means how many nodes connected to node v, and it can measure node v’s centrality
apparently. |Nv| is the number of node v’s neighbors. The degree of node v is formalized by
Equation (4), where
CD(v) = |Nv| (4)
BC: BC is the average length of the shortest paths through node v. Equation (5) is as follow:
CB(v) =
∑
s,v,t∈V
σst(v)
σst
(5)
In which, σst is the total number of shortest paths from node s to node t. σst(v) means the number
of those paths that go through node v.
CC: In the networkV withnnodes, closeness centrality means the degree that node v communicates
with other nodes set t = {t0, t1, . . . , tm}, 0 ≤ m ≤ n− 1. It is calculated by Equation (6):
Cc(v) =
n− 1∑n−1
m=0 dist(v, tm)
(6)
dist(v, t) is the distance of the shortest path from node v to node tm.
EC: EC is a measure of the influence of node v on a network. It assigns relative scores to all nodes
in the network based on the concept that connections to high-scoring nodes contribute more to the
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score of the node in question than equal connections to low-scoring nodes [30]. The EC score of node v
is shown as Equation (7):
CE(v) = αmax(v) (7)
αmax is the eigenvector corresponding to the largest eigenvalue from A which is the adjacency
matrix of KDS.
Different topology analysis methods rely on different network topology structures, which may
not comprehensively balance the importance of genes in different biological states. Therefore, we
employed four centrality indexes (one local measurement method ’DC’ and three global measurement
methods ‘BC, CC, and EC’). According to four centrality indexes, four scores of each node in the
subgraph was calculated and normalized to the number in the range 0 to 1. Each node would have a
score to evaluate the topological differences in Equation (8). Multiple centralities can be considered
comprehensively to evaluate the node topology.
ScoreT(v) = C′D(v) + C′B(v) + C
′
c(v) + C′E(v) (8)
C′D(v), C′B(v), C
′
c(v), C′E(v) means four normalized centrality indexes of node v. In the following
study, we focused on the nodes with top 10% score, which were with large topological differences in
the KDS.
2.3. Functional Enrichment Analyses
The Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses
were performed to understand the underlying biological mechanisms. GO analyses explored the
biological significance of genes by R package ‘clusterProfiler’ [31]. The enriched GO terms with
Gene-Count > 5 and p-value < 0.05 were selected for further assessment [32]. In this paper, we
also focused on the top 10% frequently occurring genes in the GO terms. The KEGG analyses were
performed on pathways with p-value < 0.05.
2.4. Evaluation Indicators
The number of essential genes in the KDS could evaluate the performance of the algorithm.
The more essential genes were found, the better the performance of the algorithm was.
PKDS =
Np
Ne
=
Np
Np +Np′
(9)
As shown in Equation (9), PKDS is calculated to evaluate the performance. Ne means the number
of essential genes.Np is the number of essential genes in KDS, and Np′ is the number of essential
genes which are not predicted in KDS. PKDS is similar to the evaluation indicator ‘Precision’ in binary
classification problem.
To better evaluate the performance, true negative (TN), false positive (FP), false negative (FN),
and true positive (TP) [33] are used to calculate evaluation indicators, including Accuracy, Precision
(PKDS), Recall, and F1-Score as following.
Accuracy =
TP+ TN
TP+ TN+ FP+ FN
(10)
PrecisionPKDS =
TP
TP+ FP
(11)
Sensitivity = Recall =
TP
TP+ FN
(12)
F1 =
2 ∗ Precision ∗Recall
Precision+ Recall
(13)
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Moreover, F1-Score is a handy indicator for measuring the accuracy of a binary classification
model. F1-Score takes Precision and Recall into account, which ranges from 0 to 1. The algorithm is
more excellent if the F1-Score is closer to 1.
3. Results and Discussion
3.1. Simulated Data Generation
According to the principles of biomolecular network [34], we used a simulated data generating
algorithm [35] to generate simulated data.
The algorithm could generate two networks with a list of essential genes and two sets of gene
expression based on some parameters. The parameters of n1 and n2 mean the number of nodes, and
m means the number of essential genes in the two networks. The parameter ρ means the proportion
of differential edges driven by perturbed genes [35]. The smaller ρ is, the more difficult it is to find
essential genes. In this paper, n1 = n2 = 100, m = 10, ρ = 0.1.
Two hundred groups of simulated datasets were generated, in which 100 groups (Dataset I) were
to get the vector (a, b) in Equation (3) and 100 groups (Dataset II) were to compare the performance of
CKDS with other methods.
As the Equation (3) shows, the score of path is influenced by
∑
dv and
∑
We, and parameter a andb
were designed to measure the importance of
∑
dv and
∑
We. In order to distinguish which variable
is more influential, the sum of a andb was designed to be 1. For each of the 100 groups (Dataset I),
the parameter a andb were taken from 0 to 1 respectively. Thus, the optimal ratio of a andb can be
generated by conducting experiments on resulted KDS’s prediction precision by Equation (11).
As shown in Figure 3, the parameter a andb around 0.5 (a : b = 1 : 1) gets the KDS with the
highest Precision (PKDS). It reflects that
∑
dv is as important as
∑
We. According to the four principles,
the CKDS algorithm considers the connectivity and scale of KDS, the topological difference of nodes
and function relevance between genes in the KDS. The reason why the ratio of a to b is 1:1 is that
when a new shortest path is added to the KDS, the ratio of the number of the points and edges is 1:1.
The newly shortest added path meets four principles very well. The value of dv and We are between 0
and 1 respectively. The ratio of
∑
dv to
∑
We is close to 1.
1 
 
 
Figure 3. Three-dimensional (3D) Surface Graph of the result of Dataset I. The x-axis and y-axis
represent the value of a and b respectively, and the z-axis represents the value of evaluation indicator
precision (PKDS).
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The experiment results showed that when the ratio of a andb is about to 1, the generated KDS
can perform well and acquire the reliable result. According to the four principles of CKDS, the final
equation to calculate the path in this paper is shown as Equation (14).
Scorepath =
∑
dv +
∑
We (14)
3.2. Comparison with other Methods on Simulated Datasets
In our work, we compared CKDS with other three differential kernel subgraph extraction
algorithms: SMT-Neurophysiology (KDS-SMT) [12], TDKS [13] and KDS based on Floyd
(KDS-Floyd) [36]. Each algorithm would get a KDS with essential genes. One hundred groups
of simulated datasets(Dataset II) with 10 essential genes were generated to assess the performance of
the four algorithms.
After calculating the evaluation indicators by Equations (10)–(13), the results show CKDS is
superior to other three algorithms on those measures (Table 1). It proves that CKDS has a good
performance to find KDS with essential genes. This is because that CKDS combines multiple principles,
which is capable of taking various kinds of differences into consideration.
Table 1. The evaluation indicators of three classical methods compared with CKDS. TKDS:
Topology-based KDS; KDS-SMT: kernel differential subgraph-Steiner Minimal Tree.
Methods
KDS-SMT KDS-Floyd TKDS CKDSIndicators
Accuracy 87.51% 81.30% 83.72% 88.86%
Precision (PKDS) 0.684 0.793 0.797 0.871
Recall 42.30% 32.29% 35.87% 46.93%
F1-Score 0.523 0.459 0.495 0.610
3.3. The Kernel Differential Subgraph Analyses for Single-Cell RNA-Seq Datasets of Glioblastoma
3.3.1. Single-Cell RNA-Seq Datasets of Glioblastoma and Fetal Human Cortical Neuron
The raw scRNA-seq data was downloaded from the GEO database. To compare GBM and
normal cells, 134 fetal human cortical neurons (FHCN) [37] (GSE67835, 25 June, 2019) and 3589 human
glioblastoma cells from Darmanis et al [38] (GSE84465, 25 June, 2019) were downloaded to discover
the KDS between two states.
Using two scRNA-seq datasets, differential expressed analyses were performed by ‘egdeR’ [14].
As shown in Figure 4a, 3547 genes were defined as DEGs. Two networks were constructed by the
method illustrated in Section 2.1.2. The GBM network consists of 912 nodes with 1986 edges and the
FHCN network consisted of 518 nodes with 594 edges. There were 387 common genes in two networks.
The common genes were sorted by calculating the graphlet vector in descending order. Finally, using
the CKDS algorithm, the KDS of GBM and FHCN was discovered, consisting of 106 genes with a total
of 141 interactions in Figure 4b.
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(a) The pre-treatment datasets of GBM and FHCN. (b) The KDS of GBM and FHCN. The bolded border
indicates the genes with high topological differences. The genes marked in red are frequently occurring
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3.3.2. The Analyses of Kernel Differential Subgraph
In order to explore the biological mechanisms of GBM, we used network topology and functional
enrichment analysis methods on the extracted KDS. Howev r, there is no g lden standard in
evaluat KDSs in real bio-network. In this paper, the eff ctiven ss of the method can be accessed by
literature mining.
According to four centrality indexes, each node in KDS was calculated by Equation (6). We focused
on the top 10% nodes with the highest scor in KDS. Eleven genes with large topological differences
(TGFB1, ITPKB, HRAS, NFKB1, PML, MYD88, ACTN1, CSF1, GAS6, DAB2 and CSNK2B) were chosen
from the KDS of GBM and FHCN in Figure 4(b). Eight of the eleven genes were supported by the
literature arguing that they had great i fluence on GBM. Among them, TGFB1, PML and GAS6 are
therapeutic targets for GBM. NFKB1, CSF1 and LYN are regulatory genes which facilitate progression
of GBM. MYD88 is biomarker to divide GBM patient. ACTN1 is regul t d during the dev lopment
of astrocytoma cells. HRAS is a driver gene that expr ssi n of oncogenic HRAS results in a malignant
phe otype in gli ma cell lines (Table 2).
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Table 2. The biological functions, corresponding PubMed IDs and literatures for genes with large
topological changes between GBM and FHCN.
Symbol: Gene Name Function Roles in GBM PMID Reference
TGFB1: transforming growth
factor beta 1
the oncogenic MSH6-CXCR4-TGFB1 feedback
loop is a novel therapeutic target for GBM 30867843 [39]
HRAS: HRas proto-oncogene,
GTPase
expression of oncogenic HRAS results in a
malignant phenotype in glioma cell lines 27834733 [40]
NFKB1: nuclear factor kappa B
subunit increase glioma cancer risk 30450997 [41]
PML: promyelocytic leukemia
a PML/SLIT1 axis regulates sensitivity to the
PML-targeting drug arsenic trioxide in primary
GBM cells
28700942 [42]
MYD88: MYD88 innate immune
signal transduction adaptor divide GBM patient 29168084 [43]
ACTN1: actinin alpha 1 influence the development of astrocytoma cells 20156433 [44]
CSF1: colony stimulating factor 1
CSF1 signaling is oncogenic during
gliomagenesis through a mechanism distinct
from modulating GAM polarization status.
27013192 [45]
GAS6: growth arrest specific 6 represent a potential new approach for gliomatreatment 18172262 [46]
The eleven genes that top 10% frequently occurred in the enriched GO terms were selected from
GBM and FHCN and marked in red in Figure 4(b). Supported by the literature, ten of the eleven genes
had great influence on GBM. Among them, EGFR, DAXX, ANXA1, ANXA2 and LYN are regulatory
genes which promote glioma growth. HSPA1B, EPHA3, INSR and TGFB1 are functional therapeutic
targets in glioblastoma (Table 3). MAP2K1 is enriched in the KEGG pathway(hsa05214) for GBM.
Table 3. The biological functions, corresponding PubMed IDs and literature references for enriched
genes by GO enrichment analyses between GBM and FHCN.
Symbol: Gene name Function roles in GBM PMID Reference
EGFR: Epidermal growth factor
receptor promote glioma growth and angiogenesis 22139077 [47]
DAXX: death domain associated
protein
targeting telomerase and ATRX/DAXX inducing
tumor senescence and apoptosis in the malignant
glioma
30625996 [48]
ANXA1: Annexin A1 enhance cancer growth and migration 29263330 [49]
ANXA2: Annexin A2
affect the proliferation of human glioma cells
through the STAT3 cyclin D1 pathway via direct
interaction with STAT3 in U251 and U87 glioma
cells
31115554 [50]
LYN: LYN proto-oncogene, Src
family tyrosine kinase
facilitate glioblastoma cell survival under
conditions of nutrient deprivation by promoting
autophagy
23936469 [51]
HSPA1B: heat shock protein family
A (Hsp70) member 1B
therapeutic targets for enhancing the efficacy of
erlotinib against GBMs 19301967 [52]
EPHA3: EPH receptor A3 a functional tumour-specific therapeutic target inglioblastoma 30562956 [53]
INSR: insulin receptor
activation of the InsR/IGF1R pathway confers
resistance to EGFR inhibitors in EGFR-dependent
glioblastoma through AKT regulation
26561558 [54]
TGFB1: transforming growth
factor beta 1
the oncogenic MSH6-CXCR4-TGFB1 feedback
loop is a novel therapeutic target for GBM 30867843 [39]
By KEGG enrichment analysis, there was an enriched KEGG pathway (hsa05214: HRAS, MAP2K1,
EGFR and CCND1) for GBM.
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In summary, by the topology and functional enrichment analyses on the KDS, seventeen genes
(nine regulatory genes, six therapeutic targets, one driver gene, one biomarker) and one pathway were
found, which were closely interrelated with GBM. The experiments indicated that the KDS extracted
by CKDS reflected the large differences between GBM and FHCN, which highly influenced on the
development of GBM.
3.4. The Kernel Differntial Subgraph Analyses for Single-Cell RNA-Seq Datasets of Neural Differentiation
3.4.1. Single-Cell RNA-Seq Datasets of Neural Differentiation
To further explore the effects of neurodevelopmental stages and the development of GBM, the raw
scRNA-seq data of neural differentiation about neural stem cell lineages from adult mice, including
152 activated neural stem cells (aNSCs), 64 produce neural progenitor cells (NPCs) and 31 astrocytes
(Asts) were downloaded from the reference [55]. Three different stages of neural stem cell lineage are
divided to Group A (aNSCs and NPCs) and Group B (NPCs and Asts).
Differential expressed analysis was performed by ‘egdeR’ packages. 1039 DEGs and 790 DEGs
were extracted from two groups respectively (Figure 5a,b). The networks were constructed by
Section 2.1.2. In Group A, the aNSCs network consisted of 504 nodes with 1492 edges and the NPCs
network consisted 686 nodes with 2682 edges. In Group B, the NPCs network consisted of 544 nodes
with 2686 edges and the Asts network consisted of 559 nodes with 2724 edges. There were 485 and
517 common genes in two groups respectively. The common genes in each group were sorted by
calculating the graphlet vector in descending order.
Biomolecules 2020, 10, 318 11 of 18 
3.4. The Kernel Differntial Subgraph Analyses for Single-Cell RNA-Seq Datasets of Neural Differentiation 
3.4.1. Single-Cell RNA-Seq Datasets of Neural Differentiation 
To further explore the effects of neurodevelopmental stages and the development of GBM, the 
raw scRNA-seq data of neural differentiation about neural stem cell lineages from adult mice, 
including 152 activated neural stem cells (aNSCs), 64 pro uce neural progenitor cells (NPCs) and 31 
astrocytes (Asts) were downloaded from the reference [55]. Three different stages of neural stem cell 
lineage are divided to Group A (aNSCs and NPCs) and Group B (NPCs and Asts). 
Differential expressed analysis was performed by ‘egdeR’ packages. 1039 DEGs and 790 DEGs 
were extracted from two groups respectively (Figure 5(a) and Figure 5(b)). The networks were 
constructed by Section 2.1.2. In Group A, the aNSCs network consisted of 504 nodes with 1492 edges 
and the NPCs network consisted 686 nodes with 2682 edges. In Group B, the NPCs network consisted 
of 544 nodes with 2686 edges and the Asts network consisted of 559 nodes with 2724 edges. Ther  
were 485 and 517 common genes in two groups respectively. The common genes in each group were 
sorted by calculating the graphlet vector in descending order.  
Usi g the CKDS algorithm, two KDSs of the two groups were discover d, consisting of 107 genes 
with 151 interactions in KDS-A and 109 genes with 144 edges in KDS-B, as shown in Figure 5(c) and 
Figure 5(d). 
 Figure 5. The datasets and KDSs of neural differentiation. The pre-treatment datasets of Group A (a)
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Using the CKDS algorithm, two KDSs of the two groups were discovered, consisting of 107 genes
with 151 interactions in KDS-A and 109 genes with 144 edges in KDS-B, as shown in Figure 5c,d.
3.4.2. Kernel Differential Subgraph Analyses
In Group A, according to four centrality indexes, top 10% genes with large topological differences
in KDS-A was calculated by Equation (6). Eleven genes (Src, Egfr, Gab1, App, Numb, Plcg1, Efnb3, Ptprk,
Actn1, Notch2 and Gsn) were chosen from the KDS-A. The border lines of these genes are bolded in
Figure 5c. Supported by the literature (Table 4), eight of the eleven genes have influence on GBM.
Among them, Src is a driver gene which inhibit the growth of GBM and reduce its survival. Egfr,
Gab1, App and Efnb3 are regulatory genes which promote glioma cell proliferation. Numb has effective
anti-cancer therapy in glioblastoma. Plcg1 induces GBM radioresistance. Notch2 and miR-181a have
potential prognostic value as tumor biomarkers in GBM patients.
Compare with Group A, only few genes (Hsp90aa1, Eprs and Hsp90ab1) supported by the literature
references in KDS-B which have influence on GBM (Table 5).
Table 4. The biological functions, corresponding PubMed IDs and literatures for genes with large
topological changes between activated neural stem cell (aNSC) and neural progenitor cells (NPC).
Symbol: Gene Name Function Roles in GBM PMID References
Src: SRC proto-oncogene,
non-receptor tyrosine kinase
Reduce human glioma stem cell
migration, invasion, and survival 28712848 [56]
Egfr: Epidermal growth factor
receptor
Promote glioma growth and
angiogenesis 22139077 [47]
Gab1: GRB2 associated binding
protein 1 Promote glioma cell proliferation 30016785 [57]
App: amyloid beta precursor
protein
Promote the proliferation of
glioma cells to inhibit the
differentiation of glioma cells
28789439 [58]
Numb: NUMB endocytic adaptor
protein Effective anti-cancer therapy 31116627 [59]
Plcg1: phospholipase C gamma 1 Induce GlioblastomaRadioresistance 26896280 [60]
Efnb3: ephrin B3 Support glioblastoma growth 28423606 [61]
Notch2: notch receptor 2 Tumor biomarkers in GBM 28389242 [62]
Table 5. The biological functions, corresponding PubMed IDs and literatures for genes with large
topological changes between NPC and astrocytes (Ast).
Symbol: Gene Name Function Roles in GBM PMID Reference
Hsp90aa1: heat shock protein 90
alpha family class A member 1 survival signatures in GBM 22952576 [63]
Eprs: glutamyl-prolyl-tRNA
synthetase the protein coding genes in GBM 30572911 [64]
Hsp90ab1: heat shock protein 90
alpha (cytosolic), class B member 1
predict prognosis in astrocytic
tumors 27258564 [65]
From aNSCs to NPCs stage, top 10% frequently occurring genes in the enriched GO terms (Rab4a,
Pten, Egfr, Rab10, Rac1, Fgfr1, Gnai1, Ntrk2, Rhob, Kras and Rhou) were selected to look for the biomarkers.
These 11 gene nodes are marked in red in Figure 5c. Supported by the literature, eight of the eleven
genes have influence on GBM. Among them, Pten and Rac1 are driver genes which inhibit the migration
and invasion of GBM. Egfr, Kras, Gnai1, Ntrk2 and Rhob are regulatory genes which drive the initiation
and progression of glioma. Fgfr1 induces GBM Radioresistance. In KDS-B, seven genes (Hsp90aa1,
Hsp90ab1, Atp1b2, Trp53, Hspa8, Usp22 and Atp1a2) are supported by the literature references which
have influence on GBM (Tables 6 and 7).
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Table 6. The biological functions, corresponding PubMed IDs and literature references for enriched
genes by GO enrichment analyses between aNSC and NPC.
Symbol: Gene Name Function Roles in GBM PMID Reference
Pten: phosphatase and tensin
homolog
Reduce human glioma stem cell migration,
invasion, and survival 28712848 [56]
Egfr: Epidermal growth factor
receptor Promote glioma growth and angiogenesis 22139077 [47]
Rac1: Rac family small GTPase 1 Inhibit the migration and invasion of glioma 28714015 [66]
Fgfr1: fibroblast growth factor
receptor 1 Induce Glioblastoma Radioresistance 26896280 [60]
Gnai1: G protein subunit alpha i1 The growth of subcutaneous and orthotopicglioma xenografts 29520106 [67]
Ntrk2: neurotrophic tyrosine
kinase, receptor, type 2 Promote tumor growth 29625067 [68]
Rhob: ras homolog family member
B
Differential implication of Rho GTPases in
morphology, proliferation rate and motility
of human glioblastoma cells
26741994 [69]
Kras: KRAS proto-oncogene,
GTPase
Drive the initiation and progression of
glioma 30946839 [70]
Table 7. The biological functions, corresponding PubMed IDs and literature references for enriched
genes by GO enrichment analyses between NPC and Ast.
Symbol: Gene Name Function Roles in GBM PMID Reference
Hsp90aa1: heat shock protein 90
alpha family class A member 1 Survival signatures in GBM 30572911 [63]
Hsp90ab1: heat shock protein 90
alpha (cytosolic), class B member 1 predict prognosis in astrocytic tumors 27258564 [65]
Atp1b2: ATPase Na+/K+
transporting subunit beta 2
Na+/K+-ATPase β2-subunit (AMOG)
expression abrogates invasion of
glioblastoma-derived brain tumor-initiating
cells.
23887941 [71]
Trp53: tumor protein p53 Induce G1/S phase cell cycle arrest inglioblastoma cells 31001122 [72]
Hspa8: heat shock protein family A
(Hsp70) member 8
Inhibition of nestin suppresses stem cell
phenotype of glioblastomas 25527454 [73]
Usp22: ubiquitin specific
peptidase 22
Increase the abilities of proliferation,
migration and invasion of glioma cells, and
promote the growth and development of
glioma
30223389 [74]
Atp1a2: ATPase, Na+/K+
transporting, alpha 2 polypeptide
Induce tumor progression and
temozolomide resistance in glioma 27837435 [75]
By KEGG enrichment analyses, the KDS enriched lots of KEGG pathways related to cancer,
particularly, the KEGG pathway mmu05214 (Egfr, Plcg1, Kras and Pten) is exactly the pathway of GBM.
In summary, the KDS-A involved ten regulatory genes, three driver genes, one biomarkers, one
therapeutic target of GBM. These fifteen genes and the KEGG pathway in KDS-A highly influenced on
the development of GBM. However, there was few genes and no pathway of GBM in KDS-B.
The topological and functional enrichment analyses indicated the genes and pathways associated
with glioma and cancers are significantly reduced during the period from NPC to Ast. It suggests that
the critical period of GBM development is from aNSC to NPC other than NPC to Ast.
Gliomas are malignant primary tumors of the central nervous system. Their cell-of-origin
is thought to be a neural progenitor or stem cell that acquires mutations leading to oncogenic
transformation [76]. By the CKDS algorithm, we proved that the stage of aNSCs to NPCs is a critical
period affecting the development of GBM.
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4. Conclusions
Complex biological networks are used to explore the mechanisms in complex diseases. Crucial
changes in different networks reflect on the development of living organisms. Therefore, it is significant
to discover the KDS leading to drastic changes.
In this work, we developed a criterion to discover KDS called CKDS. The criterion fully considered
the factors affecting KDS, including the connectivity and scale of KDS, the topological difference of
nodes and function relevance between genes in the KDS. As a result, the CKDS algorithm discovered
the KDS in different states.
The CKDS algorithm was applied to simulated datasets and three scRNA-seq datasets including
GBM, FHCN, and neural differentiation. Compared with the other state-of-art methods, the CKDS
algorithm outperformed in simulated datasets to discover the KDSs. In the scRNA-seq datasets,
we performed the network topology and functional enrichment analyses on the extracted KDSs.
Many genes, including genetic biomarkers, driver genes, regulatory genes, and therapeutic targets,
and pathways in the KDSs are closely interrelated to GBM, indicating that CKDS could express the
kernel difference between different states. Moreover, the KEGG pathway of GBM is only in neural
differentiation period from aNSC to NPC other than NPC to Ast, indicating that the period from aNSC
to NPC is an important neural differentiation period affecting the development of GBM. In addition,
the CKDS algorithm provides a unique perspective in identifying cell-type-specific genes and KDSs.
Based on the prediction of CKDS, the genes that were not supported by literature will be verified
by conducting a series of biological experiments in the future. Moreover, the CKDS algorithm can
be extended to scRNA-seq datasets of other complex diseases for detecting the molecular features of
pathogenesis mechanisms and biomarkers.
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